Consistent with this finding, our multivariable analysis of rwPFS in patients with advanced or recurrent GC treated with nivolumab plus chemotherapy identified the presence of ascites, but not the presence of peritoneal dissemination, as an independent factor associated with poor outcomes, along with ECOG PS 2–4 and decreased albumin levels. This evidence concerns the gene ALB and gastric cancer.